MAM
GHDX

Meeder Asset Management’s Genomic Health, Inc. GHDX Stock Holding History

Meeder Asset Management’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,793
Closed -$123K – 2540
2019
Q3 		$123K Sell
1,793
-3,937
-69% -$270K 0.01% 743
2019
Q2 		$333K Buy
5,730
+2,839
+98% +$168K 0.02% 473
2019
Q1 		$203K Hold
2,891
– – 0.02% 548
2018
Q4 		$186K Sell
2,891
-1,723
-37% -$121K 0.02% 515
2018
Q3 		$323K Sell
4,614
-3,951
-46% -$231K 0.02% 424
2018
Q2 		$432K Buy
8,565
+4,765
+125% +$189K 0.04% 379
2018
Q1 		$118K Buy
3,800
+840
+28% +$27.9K 0.01% 524
2017
Q4 		$101K Buy
2,960
+1,619
+121% +$51.6K 0.01% 563
2017
Q3 		$43K Buy
1,341
+420
+46% +$13.2K ﹤0.01% 714
2017
Q2 		$30K Buy
921
+604
+191% +$19.1K ﹤0.01% 755
2017
Q1 		$10K Buy
+317
New +$9.38K ﹤0.01% 868

Meeder Asset Management's GHDX Position: Q4 2019 in Review

Meeder Asset Management sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 1,793 shares — an estimated $123K sold.

Meeder Asset Management first reported a position in GHDX in Q1 2017 and held it in 11 quarters. The position peaked at $432K in Q2 2018. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.

  • Meeder Asset Management reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
  • Meeder Asset Management sold 1,793 Genomic Health, Inc. shares in Q4 2019, an estimated $123K.
  • Meeder Asset Management first reported a position in Genomic Health, Inc. in Q1 2017 and held it in 11 quarters.
  • Meeder Asset Management's Genomic Health, Inc. position peaked at $432K in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.

Based on Meeder Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.